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Abstract
In the last few years, the transfusion medicine 
community has been paying special attention to emerging 
vector-borne diseases transmitted by arboviruses. Zika 
virus is the latest of these pathogens and is responsible 
for major outbreaks in Africa, Asia and, more recently, in 
previously infection-naïve territories of the Pacific area. 
Many issues regarding this emerging pathogen remain 
unclear and require further investigation. National health 
authorities have adopted different prevention strategies. 
The aim of this review article is to discuss the currently 
available, though limited, information and the potential 
impact of this virus on transfusion medicine.
Introduction
The recognition of newly described infectious 
disease agents poses problems for health authorities 
and transfusion medicine specialists who have to 
ensure the safety of blood products. Surveillance, 
threat assessments, triggers for action, intervention 
development along with an ongoing revision of emerging 
or re-emerging infectious disease agents that pose a real 
or theoretical risk to transfusion safety play a key role 
in guaranteeing blood safety1,2. 
Recently, particular attention has been focused, also 
in industrialised countries, on vector-borne diseases 
transmitted by arboviruses (arthropod-borne viruses), 
such as West Nile, Dengue, and Chikungunya3-5. The 
risk of transmitting the above-mentioned arboviruses 
by transfusion is well known and preventive measures 
are well established3-7. 
Other arboviruses, which cause outbreaks in different 
areas of the world, are less known and there is a lack 
of data on their presence in blood during the donor's 
asymptomatic phase, the agent's survival/persistence in 
blood during processing/storage, as well as their role in 
a clinically apparent outcome in at least a proportion of 
recipients who become infected1. 
The last in the long list of emerging pathogens is 
Zika virus (ZIKAV), responsible for major outbreaks 
in previously naïve territories of the Pacific area; many 
issues regarding this pathogen remain unclear.
The aim of this review article is to discuss the 
currently available (limited) information on this virus 
focusing on the different preventive measures resulting 
from local risk assessments of its potential threat to 
public health (and transfusion) safety.
The virus 
ZIKAV is an enveloped, icosahedral, arbovirus of 
the family Flaviviridae, genus Flavivirus8 (Figure 1); 
it is phylogenetically and antigenically related to the 
Spondweni virus and is a single-stranded RNA virus 
with a positive-polarity RNA genome of approximately 
11 kb. The virus's RNA includes its complete open 
reading frame (ORF) sequence. The ORF encodes a 
polyprotein with three structural components (capsid 
[C], premembrane [prM] or membrane [M], and 
envelope [E]) and seven non-structural proteins (NS1, 
NS2a, NS2b, NS3, NS4a, NS4b, and NS5)9. 
ZIKAV was first isolated in 1947 from a Rhesus 
monkey in the Zika forest (Uganda)10. It was subsequently 
found in the Aedes (Stegomyia) Africanus mosquito 
captured in the same forest11. In 1954, the first three cases 
of human infection were reported during an epidemic 
of jaundice in Eastern Nigeria12. Interestingly, a recent 
study on the molecular evolution of this virus during 
its emergence in the 20th century showed that ZIKAV 
may have experienced several adaptive genetic changes 
(though uncommon among flaviviruses), including 
protein glycosylation patterns, which could be related 
to the lack of any clear preference for host and vector 
species13. Since its discovery, there have been ZIKAV 
outbreaks in African, Asian and Pacific regions14. In 
2007-2008, a ZIKAV epidemic occurred in the island 
of Yap (Micronesia)15, Gabon16 and Senegal
17. A major 
epidemic broke out in French Polynesia in October 2013, 
and the first autochthonous cases in New Caledonia 
were reported in January 201418. In the same year, the 
European Centre for Disease Prevention and Control 
Figure 1 - Schematic representation of the Zika virus genome.
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(ECDC) confirmed one case and reported 40 suspected 
cases on Easter Island18. At the moment, virological 
studies, seroprevalence surveys, diagnosis of sporadic 
cases, and epidemics have made it possible to identify 
the virus in Africa (Uganda, Nigeria, Ivory Coast, 
Gabon, Tanzania, Egypt, Central African Republic and 
Sierra Leone), in Asia (Cambodia, India, Indonesia, 
Malaysia, Pakistan, the Philippines, Singapore, 
Thailand and Vietnam), and in Oceania (Micronesia/
Yap, French Polynesia, New Caledonia and the Cook 
islands)14. However, in 2014, isolated cases, most of 
which imported from endemic areas, were also reported 
in Norway, Germany, Australia, France, Canada, and 
Italy14,19-23 (Figure 2).
Clinical manifestations
ZIKAV disease is a relatively unknown mosquito-
borne infection that is believed to be asymptomatic 
or mildly symptomatic in most cases and is hardly 
distinguishable from other, better-known diseases, 
caused by other arboviruses that can threaten transfusion 
safety, such as Dengue fever, West Nile or Chikungunya 
disease4-7,18,24-27. 
Although neurological complications, including 
Guillain-Barré syndrome, have been observed15,28, 
in humans, ZIKAV infection (similarly to other 
arbovirus infections) is usually characterised by mild 
fever, arthralgia (small joints of hands and feet), 
myalgia, headache, asthenia, abdominal pain, oedema, 
lymphadenopathy, retro-orbital pain, conjunctivitis, 
and cutaneous maculopapular rash. It can, therefore, be 
misdiagnosed during the acute (viraemic) phase because 
of non-specific influenza-like signs and symptoms. 
Diagnosis
The diagnosis of ZIKAV is primarily based on the 
detection of viral RNA from specimens by means of 
reverse transcription polymerase chain reaction (RT-
PCR)29. The viraemic period has not been established 
but it is believed to be short, allowing for direct virus 
detection during the first 3-5 days after the onset of 
symptoms29. In addition to the RT-PCR assay focusing on 
the detection of Micronesian ZIKAV strains30, specific 
molecular assays for Asian and African strains have been 
developed; these tests target the envelope gene or NS5 
region, the latter being more highly conserved among 
flaviviruses compared to envelope genes15,31. Recently, 
the suitability of urine samples for diagnosing ZIKAV 
infection has been confirmed, as RNA of the virus is 
detectable in urine at a higher load and with a longer 
duration than in serum32.
ZIKAV infection can also be diagnosed through 
isolation of the virus from animals or mosquitoes31,33. 
Serological tests (enzyme-linked immunosorbent 
assay [ELISA] or immunofluorescence) are also used. 
Unfortunately, there are only a few laboratories able 
to perform an ELISA for ZIKAV32. An IgM antibody 
response in primary ZIKAV-infected patients has been 
reported, but a cross-reaction with other flaviviruses, 
such as dengue virus or yellow fever virus, may make 
the diagnosis difficult15. Positive results should be 
confirmed by neutralisation assay (i.e. plaque reduction 
neutralisation test, PRNT) to document at least a 4-fold 
increase in ZIKAV neutralising antibody titres32. To this 
regard, the neutralising properties of ZIKAV antibodies 
have been exploited in PRNT and played a key role in the 
diagnosis and case classification (confirmed, probable, 
suspected, and no ZIKAV disease) of the 185 patients 
during the 2007 outbreak on Yap Island, as detailed by 
Duffy and colleagues15. 
However, as for other emerging microbial threats, 
no licensed test for ZIKAV diagnosis is currently 
available34.
Routes of transmission and potential impact on 
blood transfusion
Most arboviruses are maintained in enzootic cycles 
between haematophagous arthropod vectors and 
susceptible primary vertebrate hosts35. Humans are 
usually dead-end hosts and do not develop a sufficient 
viraemia to infect vectors efficiently but West Nile, 
Dengue, Chikungunya, and Zika virus diseases are 
important exceptions as infected patients have consistent 
levels of viraemia and can act as the primary vertebrate 
hosts in urban settings31. However, as almost all the 
more than 130 arboviruses causing human disease 
are able to be transmitted through blood transfusion, 
"the association of many mosquito-borne arboviruses 
with large, explosive outbreaks produces the greatest 
transfusion safety threat"35. 
ZIKAV has been isolated from monkeys, mosquitoes, 
and sick persons in Africa and Southeast Asia, and 
although the reservoir has not yet been identified, Figure 2 - Zika virus: outbreaks and imported cases.
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some authors suggest that it is primates15. The virus is 
transmitted to humans mainly by the Aedes mosquito 
species15. Since the first description of Aedes albopictus 
as a potential vector of ZIKAV in 2007, other Aedes 
species (Aedes aegypti, Aedes polynesiensis, Aedes 
dalzieli, etc.) have been reported as competent vectors 
of ZIKAV, which may be explained by the virus's 
molecular evolution3,13,14. Unfortunately, this implies that 
the rapidly increasing presence of this vector worldwide 
could be responsible for the emergence of new ZIKAV 
epidemics, also in urban areas3,15,28. In addition, there are 
recent reports of perinatal36, potential sexual17,23,37, and 
transfusion transmission38. Other routes of transmission 
have also been reported for West Nile39, Dengue40 and 
Chikungunya viruses41. 
In December 2013 and February 2014, Besnard and 
colleagues36 described clinical and laboratory evidence 
of two cases of perinatal transmission of ZIKAV in 
French Polynesia. 
The first hypothesis of the sexual transmission 
of ZIKAV (by semen) was advanced by Foy and 
colleagues17 who reported that the wife of a ZIKAV-
positive patient had been infected in south-eastern 
Senegal in 2008. In addition, Musso and colleagues 
demonstrated a high ZIKAV RNA load and replicative 
ZIKAV in semen samples of a patient (the virus was not 
detected by PCR in the blood sample collected at the 
same time)37, supporting the hypothesis that ZIKAV can 
be transmitted by sexual intercourse.
As far as transfusion transmission is concerned, 
considering the high rate of asymptomatic subjects 
during outbreaks, the potential blood-borne transmission 
of other arboviruses, the wide spread of the vectors also 
in countries with temperate weather3, as well as the 
recently hypothesised new routes of transmission17,36-38, 
the potential role of ZIKAV in transfusion medicine is 
plausible but still under evaluation. However, should 
autochthonous transmission of ZIKAV occur in countries 
able to supply blood components to the affected areas, 
the unavailability of a licensed laboratory test for routine 
biological qualification of blood components through 
systematic screening for ZIKAV genome by nucleic 
acid amplification tests (NAT) would probably lead 
to the adoption of blood safety (i.e. blood collection 
suspension) and self-sufficiency measures similar to 
those adopted to deal with 2007 Italian Chikungunya 
outbreak, which had considerable repercussions on the 
blood system6. 
Unfortunately, to date, there is a lack of data on 
the prevalence of ZIKAV in blood donors. The first 
molecular analyses were performed during the outbreak 
in French Polynesia and are the principal source of data38. 
RT-PCR for ZIKAV was performed in 1,505 blood 
donors and, surprisingly, an unexpectedly high number 
of positive asymptomatic blood donors (42/1,505; 3%) 
was detected. Of the blood donors positive for ZIKAV, 
11 (26.2 %) declared that they had had a "Zika fever-like 
syndrome" 3 to 10 days after donating. 
Further studies are, therefore, needed to assess the 
real seroprevalence of ZIKAV in endemic regions, to 
define the efficacy of its transmission through blood 
products and to determine its capacity to generate a 
disease in the recipient. 
Different preventive strategies for different 
countries
The tools to pinpoint the actual threat posed by 
arboviruses to blood supply safety include NAT 
(if available) of blood donors during outbreaks, 
implementing surveillance systems and improving 
cooperation between public health, virology, entomology, 
and transfusion medicine specialists to intercept possible 
transfusion-transmitted infections, as well as look-back 
studies of recipients of blood components from infected 
donors35. 
Furthermore, experience gained from dealing with 
Chikungunya outbreak6,42 showed that preparedness 
plans should encompass both: (i) preventive measures 
aimed at enhancing the vigilance towards imported 
cases of arbovirus infection to reduce the risk of 
autochthonous transmission, such as monitoring 
vector species and human cases; and (ii) blood safety 
measures such as deferral of potential donors living 
in or who have travelled to outbreak areas, NAT, risk 
algorithms to curtail blood collection if suitable NAT 
is not available, along with plans to sustain the blood 
supply and definition of an acceptable, evidence-based 
level of risk to restart blood collection. An additional and 
underestimated issue is the occurrence of co-infections 
with other arboviruses because, given the similar clinical 
features and lack of concurrent testing, they might 
not identified43. During the 2014 outbreak of ZIKAV 
infection in New Caledonia, the local arbovirus sentinel 
network enabled the diagnosis of two co-infections 
with ZIKAV and Dengue virus in patients tested with 
RT-PCR for Dengue virus, Chikungunya virus, and 
ZIKAV43. Therefore, infection with multiple pathogens 
should be kept in mind when making the differential 
diagnosis of Dengue-like illness, especially in travellers 
returning from tropical regions where the co-circulation 
of multiple arboviruses is common; in this regard, 
multiplex RT-PCR could play a crucial role in improving 
the diagnostic process in preparedness plans. 
Pathogen reduction technologies could be an 
additional efficient strategy to prevent blood-borne 
transmission of infectious pathogens, particularly 
unknown ones. Unfortunately, at the moment, no 
specific data are available on the rate of reduction (log
10
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reduction) of ZIKAV with available pathogen reduction 
technologies and we can only infer their efficacy from 
their capacity to inactivate similar pathogens44. 
At present, as far as ZIKAV preparedness plans are 
concerned, different approaches have been exploited by 
different national health authorities taking into account 
the specific local situations.
In general, in countries with sporadic imported cases 
of ZIKAV infection or in ZIKAV-free countries, no 
particular action, except notification, has been taken. 
In Australia, although ZIKAV is not endemic and 
imported cases of the disease along with the presence 
of the Aedes aegypti mosquito have been reported only 
in some coastal towns, the Queensland Government 
issued a guideline for early detection and response to 
imported and/or locally acquired cases of ZIKAV and 
to monitor the epidemiology of ZIKAV and its vector 
mosquitoes in this region45. 
Using a different strategy, in New Zealand, where the 
mosquitoes that transmit ZIKAV are not found, the New 
Zealand Ministry of Health recommended laboratory 
testing for people who have recently travelled overseas 
and have a clinical history of ZIKAV infection46. 
In Europe, according to the ECDC, blood authorities 
need to be vigilant regarding the epidemiological 
situation and should consider deferral of donors with 
travel history in line with measures defined for West 
Nile virus. Blood safety procedures are already in 
place in the Pacific region in the context of the ongoing 
outbreak of Dengue and Chikungunya and, in early 
January 2014, NAT for ZIKAV was introduced in 
French Polynesia38. Given its geographically isolated 
location, it was impossible to import fresh blood 
products into the country, so blood authorities decided 
to implement three-sample minipool ZIKAV NAT as 
soon as possible, using a modified RT-PCR, in order to 
prevent virus transmission through blood transfusion 
without discontinuing blood donations.
In France (ZIKAV is endemic in French Overseas 
Departments and mosquitoes of the Aedes species are 
present in 18 continental departments), the Ministry 
of Social Affairs and Health established increased 
monitoring of vector species and human cases. The 
purpose of this strategy is to identify cases of imported 
and indigenous arbovirus disease as soon as possible in 
order to take a series of measures aimed at reducing the 
risk of transmission during the season when the vector 
is present47.
In Italy, where arbovirus vectors are also present, 
the Ministry of Health, in addition to active surveillance 
for the early identification of imported cases, recently 
decided to start seasonal epidemiological, entomological, 
and clinical surveillance in the territories in which the 
presence of the vectors is more widespread in order 
to intercept possible autochthonous cases promptly48. 
In this regard, the first two cases of ZIKAV infection 
imported into Italy have recently been reported, 
highlighting the importance of quickly implementing 
adequate public health preventive measures, such as 
public education and mosquito bite prevention23. 
Unfortunately, at present, there are no ongoing 
entomological surveillance systems targeting vectors of 
arboviruses established in the aforementioned endemic 
(African and Pacific) regions (except in New Caledonia, 
Fiji, and French Polynesia)49.
On the other hand, in the endemic areas, where 
the capacity to control the vector is often limited or 
insufficient, strategies to limit viral circulation should 
be implemented and the possible production of a specific 
vaccine could be a valid option14.
Discussion 
Prior to 2007, only a few cases of ZIKAV infection 
had ever been described in medical literature. It was only 
in April 2007, during an outbreak on Yap Island, that the 
discovery of ZIKAV in the serum of sick patients clearly 
showed that this virus was capable of causing much more 
than isolated cases and that it had spread outside its usual 
geographic boundaries in Africa33,49. We consider that the 
potential threat of ZIKAV to transfusion safety should 
not be overlooked because "as West Nile virus aptly 
demonstrated, the unexpected should be expected"35. 
In fact, as with all arboviruses, the main problem in the 
prevention of transfusion transmission is the high rate 
of asymptomatic infections and the mild disease that can 
go unnoticed. Furthermore, as there is a viraemic period 
(albeit short) after the onset of symptoms, professionals 
charged with donor selection should very carefully 
evaluate the donation suitability after the manifestation 
of ZIKAV infection-like symptoms. In fact, arbovirus 
transfusion risk models and evaluations of viraemia 
prevalence in blood donations indicate significant 
transfusion transmission of viruses in epidemic areas. 
In conclusion, at the moment, the prevention 
strategies adopted by national health authorities are 
mainly based on active surveillance of imported 
cases and national blood authorities should consider 
the deferral of donors coming from outbreak areas. 
However, in countries that have a stable presence of 
arbovirus vectors, seasonal entomological surveillance 
should also be implemented because, as for West Nile 
virus, it could play a key role in ensuring blood safety5. 
The implementation, when possible, of systematic 
screening for ZIKAV genome through highly sensitive 
NAT would be an additional safety tool, although not 
yet available. 
In the event of a possible global increasing emergence 
of arbovirus-related diseases, all the above strategies, 
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including pathogen reduction technologies if and when 
effective, are valid tools to tackle both endemic and 
exotic pathogens that put blood safety at risk35. 
Keywords: Zika virus, arboviruses, Flaviviridae 
infections, blood transfusion, preventive health services. 
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